• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of annrheumdAnnals of the Rheumatic DiseasesCurrent TOCInstructions for authors
Ann Rheum Dis. May 2007; 66(5): 700–703.
Published online Oct 13, 2006. doi:  10.1136/ard.2006.060772
PMCID: PMC1954605

Increase of B cell‐activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production

Abstract

Background

The cytokine B cell‐activating factor of the TNF family (BAFF) is involved in the pathogenesis of autoimmune diseases.

Objective

To access changes in serum protein and mRNA levels of BAFF after rituximab treatment.

Methods

Serum and peripheral blood mononuclear cells (PBMCs) were isolated from five patients (two with lupus, two with Sjögren's syndrome, one with rheumatoid arthritis) before and 12 weeks (range 7–17) after a first course of rituximab infusion. Monocytes and B cells were selected from healthy controls and cocultured for 72 h. BAFF protein and mRNA levels were assessed by ELISA and real‐time PCR, respectively.

Results

After rituximab treatment, median serum BAFF protein level and BAFF to actin mRNA ratio in PBMCs significantly increased. In monocytes cocultured with autologous B cells, BAFF protein level decreased, whereas the mRNA level was stable. In one closely monitored patient, the mRNA ratio of BAFF to actin in PBMCs increased later than the BAFF serum level.

Conclusions

Two distinct mechanisms are probably involved in the increase in BAFF level after B cell depletion: (1) the decrease in its receptors leading to a release of BAFF; (2) a delayed regulation of BAFF mRNA transcription. This could favour the re‐emergence of autoreactive B cells.

The cytokine B cell‐activating factor of the TNF family (BAFF), also called B lymphocyte stimulator (BLyS), is mainly expressed by monocytes and plays a key role in B cell activation and survival through three receptors: BCMA, TACI, and BAFFR or BR3.1,2,3 BAFF is highly involved in the pathogenesis of autoimmune diseases.4 Thus, transgenic BAFF mice develop systemic autoimmune disease mimicking systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), primary Sjögren's syndrome (pSS), and have a delayed increase in B cell lymphoma incidence.5,6,7,8

The serum level of BAFF has been found to be increased in patients with autoimmune diseases like SLE, RA or pSS,8,9,10,11 with a correlation with the level of autoantibodies in some cases.12 These data underline the potential key role of B cells in systemic autoimmune diseases and are reinforced by the possible effectiveness of rituximab, a monoclonal anti‐CD20 antibody, demonstrated in RA13 and probably in SLE and pSS.

We therefore investigated changes in BAFF level at the protein and mRNA levels in patients with severe autoimmune disease treated with rituximab. Our results demonstrate that the BAFF level increased after rituximab treatment by two distinct mechanisms.

Patients and methods

Patients

We studied five patients with severe and refractory autoimmune diseases treated with rituximab. Two patients had pSS according to AECG criteria, including one with MALT lymphoma. One patient had RA and two had SLE according to ACR criteria. Serum and PBMCs were isolated from all patients before and 12 weeks after (range 7–17) the first rituximab infusion. Patients gave their informed consent to participate in the study, which was approved by the local ethics committee. Patient characteristics are shown in table 11.

Table thumbnail
Table 1 Patient characteristics

Cell cultures

Monocytes and B cells from the peripheral blood of four healthy donors were selected by use of anti‐CD14 and anti‐CD19 micro‐beads, respectively, and magnetic activated cell‐sorting columns (Miltenyi Biotec, Auburn, California, USA). B cell and monocyte purity was always more than 90%. Monocytes were cultured in duplicate to a final concentration of 5×105 cells/ml alone, or with autologous B cells at a ratio of 1:1 or 1:2. After 72 h culture, supernatants and cells were stored at−20°C, cells were later stored in RNA (Qiagen, Courtaboeuf, France).

ELISA

BAFF level in serum or cell supernatants was assessed by ELISA (R&D systems, Minneapolis, Minnesota, USA). The presence of rheumatoid factor in serum does not interfere with this assay.

Real‐time quantitative PCR

Total RNA was isolated from PBMCs and from cultured monocytes. BAFF and β‐actin cDNA levels were determined by quantitative RT–PCR as described previously.14 Primers were designed to be specific to full‐length BAFF, excluding any amplification of ΔBAFF.

Statistical analysis

Results are shown as means (SD). Statistical comparison involved the Wilcoxon signed ranks test using Analyse‐it for Microsoft Excel (Leeds, England, UK). p[less-than-or-eq, slant]0.05 was considered significant.

Results

BAFF serum and mRNA level evolution under rituximab treatment

Twelve weeks after the first rituximab infusion, B cells were undetectable in all evaluated patients (4/5). The median (SEM) serum protein level of BAFF increased threefold, from 1.3 (0.5) to 3.6 (1) ng/ml (p = 0.008) (fig 1A1A).

figure ar60772.f1
Figure 1 In vivo and in vitro assessment of B cell‐activating factor (BAFF) protein and mRNA level evolution after B cell depletion. (A) Serum BAFF protein level (ng/ml) before (t1) and 7–17 weeks after (t2) rituximab infusion. ...

Changes in BAFF mRNA level paralleled changes in BAFF protein level: the median (SEM) mRNA ratio of BAFF to actin in PBMCs increased from 12.8 (4.4) to 30.9 (10.4) (p = 0.05) (fig 1B1B).). Monocyte count did not vary significantly for each patient (median (SEM) increase in total count: from 400 (63.2) to 480 (68.2)/mm3.

Level of BAFF protein and mRNA in monocytes in the presence or absence of autologous B cells

We tested the hypothesis of a negative regulation of B cells on BAFF secretion by monocytes by coculturing purified monocytes and B cells from four healthy subjects. Median (SEM) BAFF protein level in supernatants as assessed by ELISA significantly decreased when monocytes were cultured in the presence of autologous B cells at ratios of both 1:2 and 1:1 (20.7 (4.9) pg/ml, p = 0.03, and 27.8 (2.8) pg/ml, p = 0.03, respectively) as compared with culture without B cells (36.3 (10) pg/ml) (fig 1C1C).). Conversely, the mean mRNA ratio of BAFF to actin did not change significantly (p = 0.3) (fig 1D1D).

BAFF protein and mRNA levels closely monitored in one patient

The sequential data obtained for mRNA and protein levels at weeks 0, 1, 2, 3 and 11 in patient 2 treated with four weekly infusions of rituximab provide some clues to understanding the phenomenon. In this patient, an increase in BAFF protein level occurred early, at week 3, whereas the BAFF mRNA level was still low at week 3 and increased between week 3 and 11 (no sample was obtained between week 3 and week 11 ) (fig 22).

figure ar60772.f2
Figure 2 Kinetics of B cell‐activating factor (BAFF) increase at both the protein and mRNA levels after rituximab infusion in one closely monitored patient. Serum BAFF protein and mRNA levels were assessed by ELISA in patient two at weeks ...

Discussion

In five patients (one with RA, two with SS and two with SLE) with severe and refractory autoimmune disease treated with rituximab, we found a significant increase in serum protein level of BAFF 12 weeks after treatment, which extends recent previous results in 15 patients with RA.15 Thus, the effect of rituximab on the serum protein level of BAFF seems to be the same in different autoimmune diseases.

The simplest mechanism proposed to explain this phenomenon is a mechanistic increase in serum BAFF level after rituximab‐induced B‐cell depletion because of the disappearance of most BAFF receptors mainly present on the surface of B cells, but other feedback mechanisms can be suggested.15,16

To determine the mechanisms involved in BAFF protein level increase after rituximab treatment, we carried out two sets of experiments.

Firstly, we used quantitative PCR to monitor BAFF mRNA level in PBMCs and ELISA to analyse BAFF levels in serum. Changes in BAFF mRNA level paralleled changes in BAFF protein level. We therefore concluded that there is a true transcriptional regulation of BAFF production induced by B‐cell depletion.

Secondly, we cocultured purified monocytes and B cells to understand the effect of B cells on BAFF mRNA expression and BAFF protein secretion by monocytes. When monocytes were cultured in the presence of autologous B cells, BAFF protein level decreased whereas BAFF mRNA levels did not change. The sequential data obtained for mRNA and protein levels at weeks 0, 1, 2, 3 and 11 in one patient treated with four weekly infusions of rituximab provide some clues to understanding this discrepancy between the in vitro and ex vivo findings. In this patient, an increase in BAFF protein level occurred early, at week 3, whereas the BAFF mRNA level was still low at week 3 and increased only between weeks 3 and 11 (no sample was obtained between weeks 3 and week 11) (fig 22).

Thus, two successive mechanisms are suggested to explain the increase in BAFF level after rituximab treatment. First, a very early mechanistic increase in the serum protein level of BAFF may occur, demonstrated ex vivo and in vitro by the early increase in protein level with a stable level of mRNA. But this mechanistic increase due to the depletion of BAFF receptors is followed by a positive transcriptional regulation of BAFF, as demonstrated by the concomitant increase in serum BAFF protein and mRNA levels in all patients, 12 weeks after rituximab infusion.

How can this transcriptional regulation of BAFF be explained? We hypothesised that a negative signal might be delivered from B cells to monocytes, thus inhibiting BAFF production. Therefore, B cell depletion could abolish this negative signal, leading to an increased transcription of BAFF mRNA. Nevertheless, coculture experiments did not demonstrate a negative effect of B cells on BAFF mRNA transcription. The absence of a decrease in the BAFF or actin mRNA ratio in cocultures could even signify a positive regulation, since BAFF mRNA expressed by monocytes and not by B cells should have been diluted with the actin expressed by B cells. A possible explanation of this discrepancy is that cocultures were performed during only 3 days because B cells could not survive in vitro any longer, and that, as observed in one patient, regulation of BAFF mRNA transcription occurred late after B‐cell depletion. Thus, we suggest that a negative regulation of B cells on BAFF mRNA transcription by monocytes could occur after a long‐term persistent interaction between B cells and monocytes. Alternatively, the positive regulation of BAFF mRNA transcription after rituximab might not be related directly to B‐cell depletion but to another indirect associated mechanism.

In conclusion, the increased serum BAFF level after rituximab infusion is probably the consequence of two distinct mechanisms: one mechanistically related to the large decrease in receptors after B‐cell depletion, and the other to delayed regulation of the BAFF mRNA level. Therefore, the serum BAFF level must be interpreted with caution after rituximab treatment and probably does not reflect the level of activity of the autoimmune disease in these patients. However, this increase in BAFF level after rituximab could favour the re‐emergence of autoreactive B cells leading to disease relapse. BAFF‐antagonist treatment could therefore be considered to prolong the period of clinical remission after rituximab infusion in refractory autoimmune diseases.

Abbreviations

BLyS - B lymphocyte stimulator

MALT - mucosa‐associated lymphoid tissue

PBMC - peripheral blood mononuclear cells

pSS - primary Sjögren's syndrome

RA - rheumatoid arthritis

SLE - systemic lupus erythematosus

Footnotes

Financial support: FL received a grant from the “Académie Nationale de Médecine” for this work.

References

1. Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 2005. 17282–289.289 [PubMed]
2. Nardelli B, Belvedere O, Roschke V, Moore P A, Olsen H S, Migone T S. et al Synthesis and release of B‐lymphocyte stimulator from myeloid cells. Blood 2001. 97198–204.204 [PubMed]
3. Ng L G, Sutherland A P, Newton R, Qian F, Cachero T G, Scott M L. et al B cell‐activating factor belonging to the TNF family (BAFF)‐R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004. 173807–817.817 [PubMed]
4. Mackay F, Sierro F, Grey S T, Gordon T P. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 2005. 8243–265.265 [PubMed]
5. Batten M, Fletcher C, Ng L G, Groom J, Wheway J, Laabi Y. et al TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 2004. 172812–822.822 [PubMed]
6. Mackay F, Woodcock S A, Lawton P, Ambrose C, Baetscher M, Schneider P. et al Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999. 1901697–1710.1710 [PMC free article] [PubMed]
7. Khare S D, Sarosi I, Xia X Z, McCabe S, Miner K , Solovyev I. et al Severe B cell hyperplasia and autoimmune disease in TALL‐1 transgenic mice. Proc Natl Acad Sci USA 2000. 973370–3375.3375 [PMC free article] [PubMed]
8. Groom J, Kalled S L, Cutler A H, Olson C, Woodcock S A, Schneider P. et al Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002. 10959–68.68 [PMC free article] [PubMed]
9. Tan S M, Xu D, Roschke V, Perry J W, Arkfeld D G, Ehresmann G R. et al Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003. 48982–992.992 [PubMed]
10. Ohata J, Zvaifler N J, Nishio M, Boyle D L, Kalled S L, Carson D A. et al Fibroblast‐like synoviocytes of mesenchymal origin express functional B cell‐activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005. 174864–870.870 [PubMed]
11. Stohl W, Metyas S, Tan S M, Cheema G S, Oamar B, Xu D. et al B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003. 483475–3486.3486 [PubMed]
12. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T. et al The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003. 62168–171.171 [PMC free article] [PubMed]
13. Edwards J C, Szczepanski L, Szechinski J, Filipowicz‐Sosnowska A, Emery P, Close D R. et al Efficacy of B‐cell‐targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004. 3502572–2581.2581 [PubMed]
14. Ittah M, Miceli‐Richard C, Eric Gottenberg J, Lavie F, Lazure T, Ba N. et al B cell‐activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther 2006. 8R51 [PMC free article] [PubMed]
15. Cambridge G, Stohl W, Leandro M J, Migone T S, Hilbert D M, Edwards J C. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006. 54723–732.732 [PubMed]
16. Miller J P, Stadanlick J E, Cancro M P. Space, selection, and surveillance: setting boundaries with BlyS. J Immunol 2006. 1766405–6410.6410 [PubMed]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...